Table 2. Tumour characteristics according to BRCA2 status and ER status (period of diagnosis 1935–2012).
|
Non-carriers |
BRCA2
mutation |
|||||
|---|---|---|---|---|---|---|
| Characteristic | ER positive n (%) | ER negative n (%) | P-value | ER positive n (%) | ER negative n (%) | P-value |
|
Size | ||||||
| Mean (mm) | 23.0 (2–110) | 26.0 (2–100) | 0.09 | 28.5 (1–110) | 23.8 (5–65) | 0.11 |
| T1⩽20 mm | 183 (59.6) | 57 (47.1) | 73 (44.0) | 32 (57.1) | ||
| T2>20 mm to 50 mm | 107 (34.9) | 54 (44.6) | 0.01 | 75 (45.2) | 23 (41.1) | 0.06 |
| T3>50 mm | 17 (5.5) | 10 (8.3) | 18 (10.8) | 1 (1.8) | ||
|
Nodal involvement | ||||||
| No | 183 (58.1) | 71 (51.1) | 0.17 | 71 (37.4) | 41 (68.3) | <0.001 |
| Yes | 132 (41.9) | 68 (48.9) | 119 (62.6) | 19 (31.7) | ||
|
Grade | ||||||
| 1 | 116 (33.5) | 15 (10.2) | 25 (12.8) | 5 (7.9) | ||
| 2 | 178 (51.5) | 53 (36.1) | <0.001 | 110 (56.4) | 23 (36.5) | 0.002 |
| 3 | 52 (15.0) | 79 (53.7) | 60 (30.8) | 35 (55.6) | ||
Abbreviation: ER=oestrogen receptor.